ServiziMenu principaleHome
You are here: Home > What we do > Past events > 2009 > ECCLU - Educational Cancer Convention Lugano
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page


CME accreditation
Application for CME accreditation has been submitted to ACOE and UEMS for EACCME, and to the Italian Ministry of Health for Italian CME.
The Convention has achieved CME accreditation approval by ACOE, which means that the programme has been recognised a high quality value both from a scientific and didactic point of view.
A request for European endorsement of ACOE accreditation has been submitted to the European Union of Medical Specialists (UEMS) clearing house, the EACCME. ACOE has recommended that the event be granted 18 European CME credits.
Furthermore, ECCLU is an ESMO-Supported meeting and has been granted 19 ESMO-MORA category 1 points


The European School of Oncology is pleased to announce that ECCLU, the Educational Cancer Convention, will be held in collaboration with the European Society for Medical Oncology in Lugano, Switzerland, from 2 to 4 July 2009.

The programme design has been lead by young oncologists to best meet the educational needs and interests of young oncologists, providing knowledge in the areas where new and important information has become available.

The aim of the Convention is to offer an update on what matters in a concise and efficient manner, offering  a refresh meeting to all those who have an established education in oncology. The Convention will also offer the opportunity to understand how knowledge should be applied in practice with the example of clinical cases brought by the participants.

Key-activity_note lectures

Topics which can and need to be presentedin a well structured way
Topics which are new and need to be discussed
Topics which the oncology community is debating on
Topics that require to be approached by more perspectives
Submitted by the participants, will be limited to case presentations to be discussed in the format of poster presentations. The best cases will be included in the plenary sessions to discussed with the faculty and participants.


General information


ESO Bellinzona Office
Ospedale Regionale Bellinzona e Valli
6500 Bellinzona, Switzerland
Tel:  +41 91 811 8050 
Fax: +41 91 811 8051

ESO Head Office
Via del Bollo, 4
20123 Milan, Italy
Tel:  +39 02 8546 451 
Fax: +39 02 8546 4545

Programme and organisation
Chatrina Melcher - ESO Bellinzona    cmelcher@eso.net
Abstracts and programme
Dolores Knupfer - ESO Bellinzona     dknupfer@eso.net
Elena Ferrerio - ESO Milan               registration@eso.net

Palazzo dei Congressi, Lugano, Switzerland
Lugano is reachable by plane via Zurich (45-minute flight or 2,5-hour train) or from Milano Malpensa airport (2-hour drive, shuttle service).

ESO is grateful to the City of Lugano for their interest and support to the organisation of ECCLU, to ESMO and FAC for their co-operation and support of travel grants.

The official language of the course will be English. No simultaneous translation will be provided.

Supplement of Annals of Oncology will contain abstracts of the invited lectures and those proposed by the participants and accepted for oral presentation, poster presentation or print only.

A limited number of travel grants are assigned on a competitive basis from among participants from middle-low income countries who have had an abstract accepted for oral or poster presentation. The CV should be submitted at the same time as the abstract indicating the amount requested for travel. Successful applicants are granted accommodation and refund of actual travel costs at the end of the Convention.

The organisers bear no responsibility for untoward events in relation with the participation in the Convention. Participants are advised to take out their own personal and travel insurance coverage.

Open air and totally free!
More information at www.estivaljazz.ch

Lugano is extremely easy to reach with several means of public transportation (the railroad, the regional Lugano-Airport) and also by means of private transport.
More information at www.lugano-tourism.ch
Airplane: Lugano-Agno Airport, situated at 6 km from the city, is an ideal point of arrival.
Train: The Lugano railroad station offers you fast and easy connections to all of the most important destinations.
Car: Lugano is served by the motorway axis that directly connects northern Europe to the Mediterranean.
Lugano (Switzerland):
The shuttle bus service guarantees regular connections between the airport and the center of Lugano from 08.00 to 18.30 (from 10.00 to 18.30 Saturday and Sunday), scheduled to match the arrival and departure of air traffic. Federal Railways Station - Airport If request the shuttle bus stopped at the hotels.  Please visit the website to view the rates: www.shuttle-bus.com
Milan-Malpensa (Italy):  Please visit the websites to obtain the time-schedule and rates, and to book your transfer. www.malpensaexpress.ch or www.starbus.ch

Amiconi Consulting can also assist you to arrange transportation to and from the Swiss airports of Lugano and Zürich and the Italian airports of Milan (Malpensa, Linate) and Bergamo (Orio alSerio - low cost airfares from Europe) and help you with touring possibilities before, during, and after the Congress.


Faculty list


M. Aapro, IMO Clinique de Genolier, FMH Oncologie-Hématologie, Genolier, CH
S. Aebi, University Hospital Bern – Inselspital, Bern, CH
A. Awada, Institut Jules Bordet, Brussels, CH
D. Berthold, Centre Hospitalier Universitaire Vaudois, Lausanne, CH
F. Cardoso, Jules Bordet Institute, Brussels, BE
F. Cavalli, Oncology Institute of Southern, Switzerland, Bellinzona, CH
A. Cervantes, Hospital Clinico Universitario, Valencia, ES
A. Colombo, A.O. Ospedale di Lecco, Lecco, IT
N. Colombo, European Institute of Oncology, Milano, IT
T. Davidson, Royal Free Hospital, London, UK
S. Di Cosimo, Vall d'Hebron University Hospital,  Barcelona, ES
A. Eniu, Cancer Institute "I. Chiricuta", Cluj-Napoca, RO
G. Freilich, The Royal Free Hospital, London, UK
M. Garassino, Ospedale Fate Bene Fratelli, Milano, IT
D. Galié-Wunder, Centre Hospitalier Universitaire Vaudois, Lausanne, CH
W. Gatzemeier, Istituto Clinico Humanitas, Milano, IT
L. Gianni, IRCCS Foundation, National Cancer Institute, Milano, IT
J. Gligorov, CancerEst APHP Tenon, Department, Paris, FR
M. Gospodarowicz, Princess Margaret Hospital, University of Toronto, Toronto, CA
F. C. Hamdy, University of Oxford - John Ratcliffe Hospital, Oxford, UK
I. Judson, The Royal Marsden Hospital, London, UK
C.H. Köhne, Klinikum Oldenburg, Oldenburg, DE
L. Licitra, IRCCS Foundation, National Cancer Institute, Milano, IT
S. Loi, Jules Bordet Institute, Brussels BE
R. Miralbell, Hopital Cantonal Université de Genève, Genève, CH
P. Pasanisi, IRCCS Foundation, National Cancer Institute, Milano, IT
A. Pasic, Institute of Oncology, Sarajevo, Bosnia and Herzegovina, BA
N. Pavlidis, University of Ioannina, Ioannina, Greece
F.A. Peccatori, European Institute of Oncology, Milano, IT
R. Popescu, Hirslanden Klinik Aarau, Aarau, CH
J.A. Schalken, University of Nijmegen, Nijmegen, NL
C. Sessa, Oncology Institute of Southern Switzerland, Bellinzona, CH
R. Stahel, University Hospital Zürich, Zurich, CH
J. Vermorken, University Hospital Antwerp, Edegem, BE


2 July


Opening session
A. Costa, CH/IT - Opening and introduction
G. Giudici, CH    - Welcome address
A. Costa, CH/IT - ESO and its activities
R. Stahel, CH    - The ESO-ESMO co-operation
C. Melcher, CH  - e-grandround programme
R. Popescu, RO - Welcome from the Scientific Committee

Moving to new strategies in lung cancer
Chair: M. Garassino, IT - Speaker: R. Stahel, CH
 15:30Key-note lecture
Adjuvant endocrine treatment of breast cancer
Chair: A. Eniu, RO - Speaker: J. Gligorov, FR

Clinical cases
Breast cancer (adjuvant)
Chair: A. Eniu, RO

 16:00 Deviation of standard adjuvant chemotherapy in breast cancer
         Elaine Dunwoodie presented by Nitesh Rohatgi
 16:15 Role of neoadjuvant chemotherapy in breast conservation surgery for invasive ductal            carcinoma
         W.M. Tai
Localised prostate cancer: Radiotherapy, surgery or watchful waiting for patients above 65?
Moderator: D. Berthold, CH
 16:30 Introduction         D. Berthold, CH


16:35 Surgery
          F. Hamdy, UK


16:50 Radiotherapy            R. Mirabell, CH 


17:05 Watchful waiting         F. Hamdy, UK
 17:20 Discussion and conclusion            D. Berthold, CH
 17:30Clinical cases
Prostate cancers
Chair:  D. Berthold, CH


17:30 A case report of a metastatic prostate cancer with thrombotic thrombocytopenic purpura
         R. Kanesvaran
 17:45 The role of neoadjuvant chemotherapy as compared to adjuvant chemotherapy in early stage,           muscle invasive urothelial tumours
         W.Y. Chay
 18:15e- grandround: interactive videoconference and session transmitted live on the Internet
Cancer on the Internet
Speaker: M. Gospodarowicz, CA - Moderator: A. Pasic, BA 
 19:00Welcome cocktail 


3 July


What is new in colon cancer treatment, advanced and adjuvantOpening session
Chair: A. Cervantes, ES - Speaker: C.H. Köhne, DE


Key-note lecture
Neoadjuvant treatment of rectal cancer: How and when to use it?
Chair: R. Popescu, RO - Speaker: A. Cervantes, ES  


Clinical cases
Gastrointestinal tumours
Chair: A. Cervantes, ES

 10:00 Double complete response in MCRC patient 
         A. De Stefano  
 10:15 Long-term survival in patient with metastatic gastro-esophageal adenocarcinoma 
         P. Stefanovski  

10:30 Microangiopathic haemolytic anaemia, disseminated intravascular coagulation and bone           marrow infiltration: A rare presentation of advanced gastric carcinoma
         G. Ioannidis   

 10:45Coffee Break
Breast cancer in young women
Chair:  S Aebi, CH - Gloria Freilich, UK - F. Peccatori, IT


11:15 Biology of breast cancer in young women
          S. Loi , BE


11:45 Breast surgery in young women                     T. Davidson, UK


12:15 Lifestyle interventions in young survivors of breast cancer                 P. Pasanisi, IT

 12:45 Preservation of fertility in patients with breast cancer: Is safety possible?             D. Galié-Wunder, CH
 13:15Poster sessions and lunch

Ovarian cancer
Chair: J. Vermorken, NL - Speaker: C. Sessa, CH


The role of adjuvant treatment of endometrial cancer
Moderator:  J. Vermorken, NL

 15:15 Introduction 
         J. Vermorken, NL
 15:25 In favour of local treatment          A. Colombo, IT
 15:45 In favour of systemic treatment             N. Colombo, IT 
 16:05 Discussion and conclusion          J. Vermorken, NL 

Clinical cases
Gynaecological cancers
Chair: C. Sessa, CH

 16:15 Value of PET-CT in asymptomatic recurrent peritoneal carcinomatosis            R. Malek  
BRCA1 positive ovarian cancer: A predisposition to therapeutic selectivity
         D. Tan 
 16:45Coffee break 

Key-note lecture
Evaluation and treatment choices in elderly cancer patients
Chair: R. Popescu, RO - Speaker: M. Aapro, CH 


Moving towards individualised treatment in malignant lymphomas
Chair: R. Stahel, CH - Speaker  F. Cavalli, CH


Clinical case
Haematological cancers
Chair: R. Stahel, CH

 18:30 Is there a cure for NK/T cell lymphoma? 
         W.M. Tai
 18:45End daily programme 


4 July


Molecular biology in oncology and its influence on clinical practice
Chair:  S. Di Cosimo, IT

 8:30 Introduction 
S. Di Cosimo, IT
 8:50 Breast cancer 
F. Cardoso, BE  
 9:10 Genito-urinary cancers 
J.A. Schalken, NL 
 9:30 Roundtable discussion   

Coffee break


Sarcoma: From basic science to clinical application
Chair: N. Pavlidis, GR - Speaker: I. Judson, UK  


Key-note lecture
Recommendations for the management of metastatic breast cancer
Chair: W. Gatzemeier, IT - Speaker: F. Cardoso, BE


Clinical cases
Breast cancer, advanced
Chair: F. Cardoso, BE


12:00 Safety and efficacy of oral capecitabine in pretreated patient with metastatic breast cancer:            A review of a clinical case
         N.A. Dekic

 12:15 Complete regression of retinal metastases in a young HER2 positive breast cancer patient            treated with lapatinib
         M. Sarti  
 12:30Poster sessions and lunch


Is sequential therapy (induction chemotherapy followed by chemo-radiation) superior to chemo-radiation alone?
Chair: L. Licitra, IT - Speaker: J. Vermorken, NL  


Targeted therapies in head and neck cancer
Chair: J. Vermorken, NL 


14:30 Potential role of targeted therapies in relation to HPV positivity         L. Licitra, IT 

 15:00 Do targeted therapies meet the promise that we expect?
         A. Awada, BE  

Clinical case
Head and neck cancers
Chair: J. Vermorken, NL

 15:30 Diagnostic challenges in a case of recurrent salivary gland tumour            N. Rohatgi   

New drug development: Most promising pathways and their translational implications
Chair: C. Sessa, CH - Speaker: L. Gianni, IT

 16:15Closing remarks and farewell coffee